Innovation to Impact Grants
This program is designed to support the logical next steps of a positive, innovative, 'high risk/high reward' research grant, with the goal of working towards or achieving a significant impact on cancer.
The Innovation to Impact Grants are designed to continue the CCS funding pipeline between successful Innovation and Impact Grants. Applicants are cautioned to carefully review the full description for details on the eligibility criteria for this funding opportunity.
Scientific focus of the program and eligibility
Innovation to Impact Grants (i2I) are intended to support the further development of significant findings based on the goals originally explored through a funded CCS Innovation Grant. Note: Only investigators with a funded Innovation Grant with a project end date between January 1, 2016 and July 31, 2019 are eligible for this program.
Applicants are required to articulate significant achievements from the original Innovation Grant (i.e., significant new knowledge, publications, intellectual property, technology development, or relevant endpoints) and clearly describe and justify the progression to the new research proposed. Applicants must also describe the potential for impact of the proposed project on cancer.
Investigators looking to explore unexpected outcomes or ideas not originally proposed in a funded Innovation Grant are encouraged to apply for a new Innovation Grant as the Innovation to Impact Grant program is designed to build upon successful outcomes from the objectives of the original Innovation grant.
Please see the eligibility and requirements section prior to creating an application.
Full application due date: January 15, 2019
Results announcement: July 2019
Anticipated start date: August 1, 2019
Application guides can be found on the EGrAMS documentation for applicants page.
It is expected that up to 12 grants will be awarded in this competition.
A special call for breast cancer research is included in this competition. For applicants wishing to be considered under the breast cancer research initiative, a relevance statement is required that explicitly demonstrates how the project is relevant to breast cancer.
Grant budgets may be up to $150,000 per year with a maximum of 3 years of funding. Grants will be non-renewable.
Funding will be provided to support the direct costs of research, including supplies, salaries, and equipment associated with the proposed work. Equipment requests should not exceed $50,000 of the requested budget however an increase in this portion of the budget will be considered as an exceptional case if the i2I application involves the development of a technology or a platform that requires specific equipment to do so. Indirect costs are not eligible.
Peer review panels
Multidisciplinary peer review committees will be assembled to review the full applications. Peer review committees will consist of scientific experts with broad expertise, along with community representatives to provide patient/survivor/caregiver perspectives.
Review panel information can be found here. Note that panel composition will be finalized after the Full Application deadline, based on best-fit for each application. CCS may determine that the creation of additional panels is necessary to accommodate the volume and breadth of applications.
Full Application structure
A maximum of one i2I grant application resulting from a single Innovation Grant is allowed and must be submitted by the Principal Investigator or Co-Principal Investigator of the original Innovation Grant.
When preparing the full application, the following will be required:
- a public summary of the proposed research (please note requirements have changed)
- a scientific abstract
- a breast cancer relevance statement (as applicable), explicitly demonstrating how the project is relevant to breast cancer.
- a demonstration of significant achievements from the stated goals in the funded Innovation Grant and discussion of the clear progression of the work outlined in the i2I proposal (no more than 2 pages of single spaced text). Progress must be a direct result of the work completed within the Innovation Grant. Note that a publication resulting from the original Innovation grant is not required but it is necessary to include a clear description of specific outcomes and include relevant preliminary data in the i2I proposal.
- a detailed scientific proposal clearly stating the aims of the project including any previous work done in the area, study design, methods and analysis; a description of the expected impact that research results will have on reducing the burden of cancer; details of the investigator(s) including which member(s) of the research team will be responsible for which aspect of the project and a rationale for their inclusion in the project, as well as a description of the research environment where the work will take place (no more than 6 pages of single spaced text)
- a vision statement explicitly describing how the proposed work could move the field forward and accelerate progress in cancer research.
- data figures/tables/charts and their associated legends (no more than 5 pages)
- submission of the original Innovation Grant proposal and scientific abstract, as well as the innovation statement.
- a budget justification related to the supplies, equipment and personnel associated with the research project. This must include the number of personnel required to complete the work and a description of their experience and/or education level and their commitment to the project. The budget request must be appropriate for the type of research proposed.
Specific guidelines for the online application are available here.
The review criteria for the full application will include the following:
- evidence of the successful testing of the hypotheses from the original Innovation Grant
- evidence of significant achievements made in the original Innovation Grant
- evidence of progression to show how the proposed work builds upon significant findings from the original Innovation Grant
- potential for impact
- feasibility and scientific merit
- qualifications and experience of the investigator(s)
- quality of the research environment
- potential for the advancement of the mission of the Canadian Cancer Society
- appropriateness of the term and amount of support requested
Multiple applications/multiple sources of funding
There must not be substantial overlap (i.e. more than 50%) with any pending application (including those at the registration, abstract or Letter of Intent submission stage) to any other CCS research program as of this competition due date. Duplicate applications will not be accepted. The onus is on the applicant to indicate the extent (or absence) of overlap. Grantees can accept funds from other sources, up to the CCS research panel recommended amount in cases where the panel approved amount exceeds the annual funding limit.
Applicants are reminded to review the eligibility and requirements section for details on scientific and financial reporting, funder acknowledgement, Canadian Cancer Society policies on open access and tobacco related funding.
Last modified on: October 18, 2018